Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 27:12:969569.
doi: 10.3389/fonc.2022.969569. eCollection 2022.

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Jwa Hoon Kim  1   2 , Gi Hwan Kim  3 , Yeon-Mi Ryu  4 , Sang-Yeob Kim  4 , Hyung-Don Kim  1 , Shin Kyo Yoon  1 , Yong Mee Cho  3 , Jae Lyun Lee  1
Affiliations

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

Jwa Hoon Kim et al. Front Oncol. .

Abstract

Purpose: Immune checkpoint inhibitors (ICIs) such as nivolumab and ipilimumab (N/I) are important treatment options for advanced renal cell carcinoma (RCC). The tumor microenvironment (TME) in these ICI-treated patients is largely unknown.

Methods: Twenty-four patients treated with N/I between July 2015 and June 2020 were analyzed. Multiplexed immunohistochemistry (mIHC) was conducted to define the TME, including various T cell subsets, B cells, macrophages, and dendritic cells.

Results: The median age of the study patients was 61 years (range, 39-80) and 75.0% of these cases were men. The objective response rate with N/I was 50.0%. The densities of the CD8+ cytotoxic T cells (P=0.005), specifically CD137+ CD8+ T cells (P=0.017), Foxp3- CD4+ helper T cells (P=0.003), Foxp3+ CD4+ regulatory T cells (P=0.045), CD68+ CD206- M1 macrophages (P=0.008), and CD68+ CD206+ M2 macrophages (P=0.021) were significantly higher in the treatment responders. At a median follow-up duration of 24.7 months, the median progression-free survival (PFS) was 11.6 months. The high densities (≥median) of Foxp3- CD4+ helper T cells (P=0.016) and CD68+ CD206- M1 macrophages (P=0.008) were significantly associated with better PFS, and the density of CD137+ CD8+ cytotoxic T cells (P=0.079) was marginally associated with better PFS. After multivariate analysis, the higher density of Foxp3- CD4+ helper T cells was independently associated with better PFS (hazard ratio 0.19; P=0.016).

Conclusion: The properties and clinical implications of the TME properties in RCC indicate that Foxp3- CD4+ helper T cells, M1 macrophages, and CD137+ CD8+ T cells are potential predictive biomarkers and treatment targets.

Keywords: immune checkpoint inhibitors; renal cell carcinoma; response; survival; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Representative examples of multiplexed immunohistochemical staining of advanced renal cell carcinoma tissue sections. (A) hematoxylin and eosin staining. (B) CD20, CD4, CD103, Foxp3, CD137, and CD8. (C) CD206, CD68, CD11c, MHCII, and PDL1. Original magnification, x 200.
Figure 2
Figure 2
Progression-free survival with nivolumab plus ipilimumab according to the densities of certain T cell subsets, CD20+ B cells, and M1 macrophages at the tumor margin. (A) Foxp3- CD4+ helper T cells, (B) CD68+ CD206- M1 macrophages, (C) CD137+ CD8+ cytotoxic T cells, (D) CD137+ CD4+ T cells, (E) CD20+ B cells.
See this image and copyright information in PMC

References

    1. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. . Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med (2018) 378:1277–90. doi: 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
    1. Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. . Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open (2020) 5:e001079. doi: 10.1136/esmoopen-2020-001079 - DOI - PMC - PubMed
    1. Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, et al. . Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer (2022) 128:2085–97. doi: 10.1002/cncr.34180 - DOI - PMC - PubMed
    1. Motzer RJ, Choueiri TK, McDermott DF, Powles T, Yao J, Ammar R, et al. . Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol (2020) 38:5009. doi: 10.1200/JCO.2020.38.15_suppl.5009 - DOI
    1. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, et al. . Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med (2020) 26:909–18. doi: 10.1038/s41591-020-0839-y - DOI - PMC - PubMed